Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | RXRA | P19793 | 14/20 | 0.46 |
| ▸ | RXRB | P28702 | 2/20 | 0.46 |
| ▸ | RXRG | P48443 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | CASP6 | P55212 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | LTC4S | Q16873 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3120710 | 0.95 | L3MBTL1 (0.51) | TSHRRXRARXRBRXRGL3MBTL1 | |
| SCHEMBL3126121 | 0.95 | TSHR (0.55) | TSHRRXRARXRBRXRGL3MBTL1 | |
| SCHEMBL3128439 | 0.92 | RXRA (0.55) | TSHRRXRARXRBRXRGPOLB | |
| SCHEMBL3123416 | 0.91 | RXRA (0.44) | TSHRRXRARXRBRXRGL3MBTL1 | |
| SCHEMBL3127725 | 0.90 | MRGPRX4 (0.47) | TSHRRXRAPOLBCASP6LMNA | |
| SCHEMBL3202677 | 0.86 | HDAC6 (0.36) | TSHRRXRARXRBRXRGL3MBTL1 | |
| SCHEMBL3127770 | 0.85 | TSHR (0.52) | TSHRRXRAPOLBCASP6L3MBTL1 | |
| SCHEMBL3131075 | 0.85 | TSHR (0.46) | TSHRRXRAPOLBCASP6L3MBTL1 | |
| SCHEMBL3192272 | 0.84 | RXRA (0.43) | TSHRRXRARXRBRXRGPOLB | |
| SCHEMBL3202322 | 0.84 | RXRA (0.43) | TSHRRXRARXRBRXRGPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029689-A1 | PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-02-04 | — | — | US | claimed |
| WO-2010003084-A2 | PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-01-07 | — | — | WO | claimed |
| US-20100029689-A1 | PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-02-04 | — | — | US | disclosed |
| US-20100029689-A1 | PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-02-04 | — | — | US | disclosed |
| US-20100029689-A1 | PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-02-04 | — | — | US | disclosed |
| WO-2010003084-A2 | PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2010-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029689-A1 | PHOSPHODIESTERASE 4 INHIBITORS | PDE4A, PDE4B, PDE3B | TSHR 1908/4885RXRA 2856/4885RXRB 2676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.